Lapatinib and trastuzumab shrinks HER2+ breast cancer in 11 days after diagnosis

(ECCO-the European CanCer Organisation) Approximately one-quarter of women with HER2 positive breast cancer, who were treated with a combination of two targeted drugs before surgery and chemotherapy, saw their tumors shrink significantly or even disappear, according to results from the UK EPHOS-B clinical trial involving 257 women with newly-diagnosed, operable HER2 positive disease.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news